Enzon Pharmaceuticals, Inc. (ENZN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Enzon Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Enzon Pharmaceuticals, Inc. (ENZN) has returned 19,029.29% so far this year and 6,947.73% over the past 12 months. Looking at the last ten years, ENZN has achieved an annualized return of 55.92%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Mar 26, 1990, ENZN's average daily return is +1.48%, while the average monthly return is +29.12%. At this rate, your investment would double in approximately 0.2 years.

Historically, 46% of months were positive and 54% were negative. The best month was Mar 2026 with a return of +11,963.2%, while the worst month was Aug 2021 at -38.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, ENZN closed higher 42% of trading days. The best single day was Mar 30, 2026 with a return of +12,451.0%, while the worst single day was Jun 5, 2013 at -49.7%.

Enzon Pharmaceuticals, Inc. has an annualized alpha of 3831.45%, beta of 0.43, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since March 27, 1990.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (75.43%) than losses (65.64%) — typical of diversified or defensive assets.
• Beta of 0.43 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ENZN ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Enzon Pharmaceuticals, Inc. (ENZN) and compare them to a chosen benchmark (S&P 500 Index).

Enzon Pharmaceuticals, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Enzon Pharmaceuticals, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Enzon Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Enzon Pharmaceuticals, Inc. was 97.92%, occurring on Dec 30, 2025. Recovery took 58 trading sessions.

The current Enzon Pharmaceuticals, Inc. drawdown is 1.76%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Enzon Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Enzon Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.